Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction notification and does not contain comprehensive financial statements.
Material Changes
The filing details a specific transaction where Ms. C Thomas increased her personal holding of Ordinary Shares. The increase consisted of 32,756 shares purchased at a price of 1,617 pence per share on October 3, 2013. This transaction resulted from the re-investment of the dividend paid to shareholders on that date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the share transaction.
Investor Verification Points
- Verify the total shareholding of Ms. C Thomas following the acquisition of 32,756 shares.
- Confirm the dividend reinvestment plan terms applicable to the October 3, 2013 dividend payment.
- Check the market price of GSK shares on October 3, 2013, to validate the 1,617 pence transaction price.